Reminder of Class Action Lawsuits for Multiple Companies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: Globenewswire
- Eos Energy Lawsuit: Eos Energy Enterprises faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging failure to meet production and capacity utilization targets, which could undermine investor confidence and future financing capabilities.
- Soleno Therapeutics Risks: Soleno Therapeutics is implicated in a lawsuit covering March 26, 2025, to November 4, 2026, for allegedly downplaying safety concerns in its DCCR clinical trials, potentially leading to greater safety risks and lower market acceptance post-commercialization, impacting future profitability.
- Nektar Therapeutics Misconduct: Nektar Therapeutics is involved in a class action for the period from February 26, 2025, to December 15, 2025, with allegations of not adhering to trial protocols in the REZOLVE-AA trial, which could jeopardize trial integrity and investor trust.
- Driven Brands Financial Errors: Driven Brands faces a lawsuit for the period from May 9, 2023, to February 24, 2026, alleging multiple financial reporting errors that misrepresented cash flows and revenues, potentially leading to regulatory scrutiny and reputational damage.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 73.180
Low
102.00
Averages
123.43
High
165.00
Current: 73.180
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuits for Multiple Companies
- Eos Energy Lawsuit: Eos Energy Enterprises faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging failure to meet production and capacity utilization targets, which could undermine investor confidence and future financing capabilities.
- Soleno Therapeutics Risks: Soleno Therapeutics is implicated in a lawsuit covering March 26, 2025, to November 4, 2026, for allegedly downplaying safety concerns in its DCCR clinical trials, potentially leading to greater safety risks and lower market acceptance post-commercialization, impacting future profitability.
- Nektar Therapeutics Misconduct: Nektar Therapeutics is involved in a class action for the period from February 26, 2025, to December 15, 2025, with allegations of not adhering to trial protocols in the REZOLVE-AA trial, which could jeopardize trial integrity and investor trust.
- Driven Brands Financial Errors: Driven Brands faces a lawsuit for the period from May 9, 2023, to February 24, 2026, alleging multiple financial reporting errors that misrepresented cash flows and revenues, potentially leading to regulatory scrutiny and reputational damage.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose the unsustainable growth rate of its U.S. electrophysiology segment, misleading investors about its prospects, with a lead plaintiff motion deadline of May 4, 2026.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for failing to achieve the production ramp and capacity utilization expected from November 5, 2025, to February 26, 2026, impacting investor confidence, with a lead plaintiff motion deadline of May 5, 2026.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action from March 26, 2025, to November 4, 2026, of concealing safety concerns related to its DCCR clinical trial, leading to misconceptions about its commercial viability, with a lead plaintiff motion deadline of May 5, 2026.
- Nektar Therapeutics Errors: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for not adhering to REZOLVE-AA trial standards from February 26, 2025, to December 15, 2025, which may significantly affect trial results, with a lead plaintiff motion deadline of May 5, 2026.
See More
Faruqi & Faruqi Investigates Nektar Securities Litigation
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential securities fraud claims against Nektar Therapeutics, particularly for investors who purchased securities between February 26, 2025, and December 15, 2025, indicating possible legal liabilities for the company.
- Trial Results Failure: Nektar's press release on December 16, 2025, revealed that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, which directly undermined investor confidence.
- Legal Rights Reminder: Faruqi & Faruqi reminds investors that May 5, 2026, is the deadline to apply to serve as lead plaintiff in the federal securities class action, emphasizing the importance of timely action to protect their legal rights.
- Information Solicitation: The firm encourages anyone with information regarding Nektar's conduct, including former employees and shareholders, to come forward, demonstrating a commitment to a thorough investigation of the case.
See More
Nektar Therapeutics Investors Reminder for Upcoming Lawsuit Deadline
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that May 5, 2026, is the deadline to file a lead plaintiff motion in the class action concerning Nektar Therapeutics securities purchased between February 26 and December 15, 2025.
- Stock Price Impact: On December 16, 2025, Nektar announced that its alopecia treatment trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.8%, which directly harmed investors.
- False Statements Allegations: The lawsuit alleges that throughout the class period, Nektar failed to disclose significant adverse facts regarding the REZOLVE-AA trial, misleading investors about the company's prospects and operations, which could have influenced their investment decisions.
- Participation Information: Investors who purchased Nektar securities during the class period may apply to be lead plaintiffs by the deadline, with the law firm offering consultations to help investors understand their legal rights.
See More
Nektar Faces Securities Class Action Over Trial Enrollment Issues
- Lawsuit Background: Nektar Therapeutics is facing a class action lawsuit for allegedly including four ineligible patients in the REZOLVE-AA trial, with investors having until May 5, 2026, to seek lead plaintiff status for compensation.
- Stock Price Impact: On December 16, 2025, Nektar's shares fell by $4.14, or 7.77%, closing at $49.16, reflecting market concerns regarding the company's clinical trial compliance.
- Trial Compliance Issues: The lawsuit claims that Nektar failed to enforce strict enrollment criteria, resulting in the randomization of ineligible patients, which could compromise the trial's primary endpoint and damage investor confidence.
- Misleading Management Claims: Nektar's management previously touted
See More
Reminder of Shareholder Lawsuits Against Nektar and Eos Energy
- Nektar Lawsuit Overview: A shareholder class action lawsuit against Nektar Therapeutics alleges that the company made materially false or misleading statements between February 26, 2025, and December 15, 2025, leading to significant investor losses, with a deadline of May 5, 2026, to apply as lead plaintiff.
- Eos Energy Lawsuit Overview: The class action lawsuit against Eos Energy Enterprises, Inc. claims the company failed to achieve the production ramp and capacity utilization necessary to meet its guidance from November 5, 2025, to February 26, 2026, with the same May 5, 2026, deadline for lead plaintiff applications.
- Legal Consultation Information: Holzer & Holzer encourages investors who purchased shares during the relevant periods and suffered losses to contact their attorneys to discuss legal rights, with contact options including email and a toll-free phone number.
- Law Firm Background: Since its founding in 2000, Holzer & Holzer has focused on vigorous representation of shareholders, recovering hundreds of millions of dollars for victims of fraud and corporate misconduct, and has been rated as a top securities litigation firm from 2021 to 2025.
See More
Reminder of Class Action Lawsuits for Multiple Companies
- Eos Energy Lawsuit: Eos Energy Enterprises faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging failure to meet production and capacity utilization targets, which could undermine investor confidence and future financing capabilities.
- Soleno Therapeutics Risks: Soleno Therapeutics is implicated in a lawsuit covering March 26, 2025, to November 4, 2026, for allegedly downplaying safety concerns in its DCCR clinical trials, potentially leading to greater safety risks and lower market acceptance post-commercialization, impacting future profitability.
- Nektar Therapeutics Misconduct: Nektar Therapeutics is involved in a class action for the period from February 26, 2025, to December 15, 2025, with allegations of not adhering to trial protocols in the REZOLVE-AA trial, which could jeopardize trial integrity and investor trust.
- Driven Brands Financial Errors: Driven Brands faces a lawsuit for the period from May 9, 2023, to February 24, 2026, alleging multiple financial reporting errors that misrepresented cash flows and revenues, potentially leading to regulatory scrutiny and reputational damage.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose the unsustainable growth rate of its U.S. electrophysiology segment, misleading investors about its prospects, with a lead plaintiff motion deadline of May 4, 2026.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for failing to achieve the production ramp and capacity utilization expected from November 5, 2025, to February 26, 2026, impacting investor confidence, with a lead plaintiff motion deadline of May 5, 2026.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action from March 26, 2025, to November 4, 2026, of concealing safety concerns related to its DCCR clinical trial, leading to misconceptions about its commercial viability, with a lead plaintiff motion deadline of May 5, 2026.
- Nektar Therapeutics Errors: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for not adhering to REZOLVE-AA trial standards from February 26, 2025, to December 15, 2025, which may significantly affect trial results, with a lead plaintiff motion deadline of May 5, 2026.
See More
Faruqi & Faruqi Investigates Nektar Securities Litigation
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential securities fraud claims against Nektar Therapeutics, particularly for investors who purchased securities between February 26, 2025, and December 15, 2025, indicating possible legal liabilities for the company.
- Trial Results Failure: Nektar's press release on December 16, 2025, revealed that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.77%, which directly undermined investor confidence.
- Legal Rights Reminder: Faruqi & Faruqi reminds investors that May 5, 2026, is the deadline to apply to serve as lead plaintiff in the federal securities class action, emphasizing the importance of timely action to protect their legal rights.
- Information Solicitation: The firm encourages anyone with information regarding Nektar's conduct, including former employees and shareholders, to come forward, demonstrating a commitment to a thorough investigation of the case.
See More
Nektar Therapeutics Investors Reminder for Upcoming Lawsuit Deadline
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that May 5, 2026, is the deadline to file a lead plaintiff motion in the class action concerning Nektar Therapeutics securities purchased between February 26 and December 15, 2025.
- Stock Price Impact: On December 16, 2025, Nektar announced that its alopecia treatment trial failed to achieve statistical significance, resulting in a stock price drop of $4.14, or 7.8%, which directly harmed investors.
- False Statements Allegations: The lawsuit alleges that throughout the class period, Nektar failed to disclose significant adverse facts regarding the REZOLVE-AA trial, misleading investors about the company's prospects and operations, which could have influenced their investment decisions.
- Participation Information: Investors who purchased Nektar securities during the class period may apply to be lead plaintiffs by the deadline, with the law firm offering consultations to help investors understand their legal rights.
See More
Nektar Faces Securities Class Action Over Trial Enrollment Issues
- Lawsuit Background: Nektar Therapeutics is facing a class action lawsuit for allegedly including four ineligible patients in the REZOLVE-AA trial, with investors having until May 5, 2026, to seek lead plaintiff status for compensation.
- Stock Price Impact: On December 16, 2025, Nektar's shares fell by $4.14, or 7.77%, closing at $49.16, reflecting market concerns regarding the company's clinical trial compliance.
- Trial Compliance Issues: The lawsuit claims that Nektar failed to enforce strict enrollment criteria, resulting in the randomization of ineligible patients, which could compromise the trial's primary endpoint and damage investor confidence.
- Misleading Management Claims: Nektar's management previously touted
See More
Reminder of Shareholder Lawsuits Against Nektar and Eos Energy
- Nektar Lawsuit Overview: A shareholder class action lawsuit against Nektar Therapeutics alleges that the company made materially false or misleading statements between February 26, 2025, and December 15, 2025, leading to significant investor losses, with a deadline of May 5, 2026, to apply as lead plaintiff.
- Eos Energy Lawsuit Overview: The class action lawsuit against Eos Energy Enterprises, Inc. claims the company failed to achieve the production ramp and capacity utilization necessary to meet its guidance from November 5, 2025, to February 26, 2026, with the same May 5, 2026, deadline for lead plaintiff applications.
- Legal Consultation Information: Holzer & Holzer encourages investors who purchased shares during the relevant periods and suffered losses to contact their attorneys to discuss legal rights, with contact options including email and a toll-free phone number.
- Law Firm Background: Since its founding in 2000, Holzer & Holzer has focused on vigorous representation of shareholders, recovering hundreds of millions of dollars for victims of fraud and corporate misconduct, and has been rated as a top securities litigation firm from 2021 to 2025.
See More
